132
Participants
Start Date
August 31, 2010
Primary Completion Date
August 31, 2011
Study Completion Date
August 31, 2011
Insulin lispro
Insulin aspart
Recombinant human hyaluronidase PH20
Insulin glulisine
Insulin glargine
Medstar Research Institute, Hyattsville
Diabetes and Endocrinology Associates, PC, Rudd
Center for Diabetes and Endocrine Care, Hollywood
Diabetes Research Institute, Miami
Baptist Diabetes Associates, Miami
Henry Ford Health System, Detroit
International Diabetes Center, Minneapolis
Mercury Street Medical, Butte
Mid-America Diabetes Associates, Wichita
Tulane University Health Sciences Center, New Orleans
UT Southwestern Medical Center at Dallas, Dallas
Cetero Research-San Antonio, San Antonio
Texas Diabetes and Endocrinology, Round Rock
Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls
Desert Endocrinology, Henderson
Medical Group of Encino, Encino
AMCR Institute, Inc., Escondido
Mills-Peninsula Health Services, San Mateo
John Muir Physician Network Clinical Research Center, Concord
Marin Endocrine Care and Research, Greenbrae
University of Washington School of Medicine, Seattle
West Olympia Internal Medicine, Olympia
Lead Sponsor
Halozyme Therapeutics
INDUSTRY